Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 590-599

  Schild, S E ^a   Vokes, E E ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Immunotherapy; Nonsmall cell lung cancer; Radiation therapy; Review; Targeted therapy

Indexed keywords

AE 941; AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; DURVALUMAB; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; METFORMIN; MITOMYCIN; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; TECEMOTIDE; THALIDOMIDE; VELIPARIB; VINBLASTINE; VINDESINE; ANTINEOPLASTIC AGENT;

CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; DRUG EFFICACY; DYSPHASIA; HEMOPTYSIS; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INDUCTION CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; THORACIC RADIOTHERAPY; ADVERSE DRUG REACTION; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; MULTIMODALITY CANCER THERAPY; NORTH AMERICA; PATHOLOGY; THORAX RADIOGRAPHY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NORTH AMERICA; RADIOGRAPHY, THORACIC;

EID: 84964670270     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv621     Document Type: Review

References (67)

1. Wolf J, Patno ME, Roswit B, D'Esopo N. Controlled study of survival of patients with clinically inoperable lung cancer treated with radiation therapy. Am J Med 1966; 40: 360-367.
2. Roswit B, Patno ME, Rapp R et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968; 90: 688-697.
3. Perez CA, Pajak TF, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874-1881.
4. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III nonsmall- cell lung cancer. N Engl J Med 1990; 323: 940-945.
5. Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage III non-smallcell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215.
6. Sause WT, Scott C, Taylor S et al. Radiation Therapy Oncology Group (RTOG) 88- 08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
7. Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994; 10(Suppl 1): S239-S244.
8. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
9. Atagi S, Kawahara M, Yokoyama A et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13: 671-678.
10. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
11. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
12. Clamon G, Herndon J, Eaton W et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. Cancer Invest 1994; 12: 273-282.
13. Curran WJ, Jr, Paulus R, Langer CJ et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-1460.
14. Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-5917.
15. Ulutin HC, Guden M, Oysul K et al. Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer. Radiat Med 2000; 18: 93-96.
16. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
17. Chen M, Bao Y, Ma HL et al. Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced nonsmall cell lung cancer: a prospective randomized study. Biomed Res Int 2013; 2013: 371819.
18. Schild SE, Stella PJ, Geyer SM et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54: 370-378.
19. Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187-199.
20. Fernandes AT, Shen J, Finlay J et al. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes. Radiother Oncol 2010; 95: 178-184.
21. Eaton BR, Pugh SL, Bradley JD et al. The effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer treated with chemoradiation: a report of the Radiation Therapy Oncology Group (RTOG) 0617. J Clin Oncol 2014; 32 (5s suppl): abstr 7551.
22. Le Pechoux C, Mauguen A, Schild SE et al. Accelerated or hyperfractionated radiotherapy (RT) versus conventional RT in non-metastatic lung cancer (LC): individual patient data (IPD) meta-analysis from 2279 patients (PTS). J Thorac Oncol 2010; 5: S73.
23. Mauguen A, Le Pechoux C, Saunders MI et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 2788-2797.
24. Vokes EE, Herndon JE, II, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-1704.
25. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760.
26. Ahn JS, Ahn YC, Kim JH et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol 2015; 33: 2660-2666.
27. Segawa Y, Kiura K, Takigawa N et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010; 28: 3299-3306.
28. Wang L, Wu S, Ou G et al. Randomized phase II study of concurrent cisplatin/ etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012; 77: 89-96.
29. Yamamoto N, Nakagawa K, Nishimura Y et al. Phase III study comparing secondand third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010; 28: 3739-3745.
30. Santana-Davila R, Devisetty K, Szabo A et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration Data. J Clin Oncol 2015; 33: 567-574.
31. Senan S, Brade AM, Wang L et al. Final overall survival (OS) results of the phase III PROCLAIM trial: pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). J Clin Oncol 2015; 33 (15 suppl): abstr 7506.
32. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
33. Wozniak AJ, Moon J, Thomas CR, Jr. et al. A pilot trial of cisplatin/etoposide/ radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015; 16: 340-347.
34. Lu C, Lee JJ, Komaki R et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010; 102: 859-865.
35. Walraven I, Van Den Heuvel M, Schaake E et al. Radiation dose escalation in patients with locally advanced non-small cell lung cancer; 60 month follow-up of a randomized phase II trial. J Thorac Oncol 2015; 10: s212-s213.
36. Spigel DR, Hainsworth JD, Yardley DA et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28: 43-48.
37. Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III nonsmall- cell lung cancer. J Clin Oncol 2012; 30: e104-e108.
38. Butts C, Socinski MA, Mitchell PL et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68.
39. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105: 595-605.
40. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-151.
41. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
42. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-2177.
43. Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: a new era of targeted therapy. Maturitas 2015; 81: 5-9.
44. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
45. Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non- SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33: LBA109.
46. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
47. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7: e33411.
48. Storozhuk Y, Hopmans SN, Sanli T et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013; 108: 2021-2032.
49. Currie CJ, Poole CD, Jenkins-Jones S et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
50. Tan BX, Yao WX, Ge J et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011; 117: 5103-5111.
51. Saxena A, Becker D, Preeshagul I et al. Therapeutic effects of repurposed therapies in non-small cell lung cancer: what is old is new again. Oncologist 2015; 20: 934-945.
52. Schild SE, Bonner JA, Hillman S et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol 2007; 25: 3124-3129.
53. Belderbos J, Uitterhoeve L, van Zandwijk N et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007; 43: 114-121.
54. Tsoutsou PG, Froudarakis ME, Bouros D, Koukourakis MI. Hypofractionated/ accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res 2008; 28: 1349-1354.
55. Bral S, Duchateau M, Versmessen H et al. Toxicity report of a phase 1/2 doseescalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer 2010; 116: 241-250.
56. Matsuura K, Kimura T, Kashiwado K et al. Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/ paclitaxel in the treatment of locally advanced non-small-cell lung cancer. Int J Clin Oncol 2009; 14: 408-415.
57. Casas F, Vinolas N, Ferrer F et al. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer. J Thorac Oncol 2011; 6: 79-85.
58. Maguire J, Khan I, McMenemin R et al. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer 2014; 50: 2939-2949.
59. Maguire J, O'Rourke N, McNememin R et al. Soccar: internationally resonant results from a randomised trial based on UK clinical practice. Thorax 2012; 67: A47.
60. Lin Q, Liu YE, Ren XC et al. Dose escalation of accelerated hypofractionated threedimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial. Radiat Oncol 2013; 8: 201.
61. van den Heuvel MM, Uyterlinde W, Vincent AD et al. Additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother Oncol 2014; 110: 126-131.
62. Bearz A, Minatel E, Rumeileh IA et al. Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer 2013; 13: 513.
63. Karam SD, Horne ZD, Hong RL et al. Dose escalation with stereotactic body radiation therapy boost for locally advanced non-small cell lung cancer. Radiat Oncol 2013; 8: 179.
64. Feddock J, Arnold SM, Shelton BJ et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2013; 85: 1325-1331.
65. Sejpal S, Komaki R, Tsao A et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2011; 117: 3004-3013.
66. Lundkvist J, Ekman M, Ericsson SR et al. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005; 103: 793-801.
67. Moriarty JP, Borah BJ, Foote RL et al. Cost-effectiveness of proton beam therapy for intraocular melanoma. PLoS One 2015; 10: e0127814.